<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC6973187/results/search/test_trace/results.xml">
  <result pre="high incidences of morbidity and mortality. In HSCT patients, the" exact="infection" post="risk is increased until immune reconstitution is re-established. Therapy"/>
  <result pre="as the HAdV viral load (VL) increased to 132 × 106 copies/ml," exact="treatment" post="with 5 mg/kg weekly intravenous cidofovir with concomitant hydration only"/>
  <result pre="no other concomitant drugs that could have caused cholestasis, BCV" exact="treatment" post="was stopped and Cidofovir was restarted. However, as HAdV"/>
  <result pre="occurs via droplet, feco-oral, and direct spread [5]. After primary" exact="infection" post="the virus remains latent in the lymphoreticular system. In"/>
  <result pre="with a reasonably safe toxic profile [8]. Treatment of HAdV" exact="infection" post="in immunocompromised patients is ineffective without immune reconstitution [6,"/>
  <result pre="includes nausea, vomiting, myelosuppression and severe renal tubulopathies [8]. During" exact="treatment" post="the direct and indirect costs increase due to in-hospital"/>
  <result pre="consuming with complex administration procedures [12]. In LMIC, high viral" exact="infection" post="susceptibilities in patients with HIV, malnutrition, chronic diseases, malignancies,"/>
  <result pre="availability is guaranteed. 3. Conclusion BCV can successfully treat HAdV" exact="infection" post="in post-transplant immunocompromised children. Although direct drug costs have"/>
  <result pre="authors have no conflicts of interest to declare. References 1FeuchtingerT.LangP.HandgretingerR.Adenovirus" exact="infection" post="after allogeneic stem cell transplantationLeukemia &amp;amp; Lymphoma200748224425510.1080/1042819060088115717325884 2WallsT.ShankarA.ShingadiaD.Adenovirus: an"/>
  <result pre="haploidentical donors in children: an updateKlinische Pädiatrie2005217633934410.1055/s-2005-87253016307420 7TaniguchiK.YoshiharaS.TamakiH.et al.Incidence and" exact="treatment" post="strategy for disseminated adenovirus disease after haploidentical stem cell"/>
  <result pre="Immunology20167p. 50010.3389/fimmu.2016.00500 Figure 1 The viral load response during the" exact="treatment" post="with Cidofovir and Brincidofovir. Figure 2 Pharmacokinetics and drug"/>
 </snippets>
</snippetsTree>
